PDF(Pubmed)
Abstract：
The aging of our societies leads to a higher prevalence of multimorbidity and therefore polypharmacy, which often results in inappropriate drug treatment. To address this issue, numerous listing approaches, such as the Fit fOR The Aged (FORTA) list have been developed. FORTA\'s positive impact on the quality of medications and relevant clinical outcomes has been shown. Based on new emerging evidence and experiences with the existing FORTA lists, we aimed to update the FORTA lists in several European countries/regions.
Two-step Delphi consensus procedures were conducted in Poland, UK/Ireland, Italy, Spain, the Nordic countries, The Netherlands and France. The existing European FORTA lists served as survey proposals.
Thirty-two experts agreed to take part in this study (return rate: 96.9%). The country/region-specific overall consensus for all items and participants after the first round was > 90%. FORTA lists from six participating countries, plus the FORTA list for the German-speaking countries, were collated into the new EURO-FORTA List, which now contains 267 items aligned to 27 indications. Three items were added to the EURO-FORTA List, and no drugs were deleted. Eight FORTA items were relabeled, and 96.9% of the labels remained unchanged.
In this study, seven new country/region specific FORTA lists, as well as a new overarching EURO-FORTA List, were developed. An overall increase in the mean consensus coefficient and increases for all disease-specific mean consensus coefficients show a wider consensus among participants. The new lists have the potential to improve drug therapy in older people internationally.
Two-step Delphi consensus procedures were conducted in Poland, UK/Ireland, Italy, Spain, the Nordic countries, The Netherlands and France. The existing European FORTA lists served as survey proposals.
Thirty-two experts agreed to take part in this study (return rate: 96.9%). The country/region-specific overall consensus for all items and participants after the first round was > 90%. FORTA lists from six participating countries, plus the FORTA list for the German-speaking countries, were collated into the new EURO-FORTA List, which now contains 267 items aligned to 27 indications. Three items were added to the EURO-FORTA List, and no drugs were deleted. Eight FORTA items were relabeled, and 96.9% of the labels remained unchanged.
In this study, seven new country/region specific FORTA lists, as well as a new overarching EURO-FORTA List, were developed. An overall increase in the mean consensus coefficient and increases for all disease-specific mean consensus coefficients show a wider consensus among participants. The new lists have the potential to improve drug therapy in older people internationally.
摘要：
背景：我们社会的老龄化导致多发病的患病率更高，因此多药，这通常会导致不适当的药物治疗。为了解决这个问题，众多的上市方法，例如，已经制定了适合老年人(FORTA)名单。已显示FORTA对药物质量和相关临床结果的积极影响。根据现有FORTA名单的新证据和经验，我们的目标是更新几个欧洲国家/地区的FORTA名单。
方法：在波兰进行了两步德尔菲共识程序，英国/爱尔兰,意大利,西班牙,北欧国家,荷兰和法国。现有的欧洲FORTA名单作为调查建议。
结果：32名专家同意参加本研究（回报率：96.9%）。第一轮后，所有项目和参与者的国家/地区特定总体共识>90%。FORTA列出了来自六个参与国的名单，加上德语国家的FORTA名单，被整理到新的EURO-FORTA名单中，现在包含与27个指示对齐的267个项目。三个项目被添加到EURO-FORTA列表中，没有药物被删除。八个FORTA项目被重新标记，96.9%的标签保持不变。
结论：在这项研究中，七个新的国家/地区特定FORTA名单，以及新的总体欧元-FORTA名单，是开发的。平均共识系数的总体增加和所有特定疾病的平均共识系数的增加表明参与者之间的共识更广泛。新名单有可能改善国际老年人的药物治疗。
方法：在波兰进行了两步德尔菲共识程序，英国/爱尔兰,意大利,西班牙,北欧国家,荷兰和法国。现有的欧洲FORTA名单作为调查建议。
结果：32名专家同意参加本研究（回报率：96.9%）。第一轮后，所有项目和参与者的国家/地区特定总体共识>90%。FORTA列出了来自六个参与国的名单，加上德语国家的FORTA名单，被整理到新的EURO-FORTA名单中，现在包含与27个指示对齐的267个项目。三个项目被添加到EURO-FORTA列表中，没有药物被删除。八个FORTA项目被重新标记，96.9%的标签保持不变。
结论：在这项研究中，七个新的国家/地区特定FORTA名单，以及新的总体欧元-FORTA名单，是开发的。平均共识系数的总体增加和所有特定疾病的平均共识系数的增加表明参与者之间的共识更广泛。新名单有可能改善国际老年人的药物治疗。
